Sign In

Cain McClary, MD

Science Venture Capital

Cain McClary, MD, is a prominent physician-scientist and venture capitalist, currently serving as a Clinical Instructor and Visiting Professor at Tulane University School of Medicine. He is also the Founder and Managing Partner of KdT Ventures, a venture capital firm focused on supporting innovative startups in the life sciences sector.

Educational Background

  • Undergraduate Degree: McClary earned his Sc.B. in Biochemistry and Molecular Biology from Brown University in 2007.
  • Medical Degree: He obtained his MD from Tulane University School of Medicine in 2012. During his medical education, he participated in the prestigious Howard Hughes Medical Institute “Cloister” Fellowship at the National Institutes of Health (NIH), where he researched non-coding RNA's role in cancer at the National Cancer Institute (NCI) under Dr. Curtis Harris.13

Professional Experience

  • Residency: Following medical school, McClary completed his residency in Anatomic Pathology at Stanford University, where he was named Chief Resident in his final year. He discovered a genetic mutation linked to ameloblastoma, leading to significant advancements in treatment options for this condition.13
  • Academic Roles: After residency, he became an Assistant Professor in the Department of Pathology at Stanford University, making him one of the youngest faculty members in that department.14
  • KdT Ventures: In 2017, he founded KdT Ventures, which has since invested in numerous early-stage science and technology companies. The firm is recognized for its focus on transformative science and has managed approximately $280 million across various sectors including healthcare and agriculture.23

Current Contributions

As a Clinical Instructor at Tulane University, McClary engages in teaching and mentoring medical students while also contributing to research initiatives. His dual role as an educator and investor allows him to bridge the gap between scientific innovation and practical application in healthcare.45

McClary's extensive experience combines clinical practice with venture capital, positioning him as a key figure at the intersection of medicine and technology. He actively advises startups and institutional investors, leveraging his background to foster advancements that can have significant impacts on human health.23

Highlights

Nov 4 · biotechtv.com
KdT Ventures' Founder and Managing Partner Cain McClary
Jul 20 · bios.community
20. VC Firm Building: Cain McClary - Founder @ KdT Ventures
May 23 · Pulse 2.0
Elegen: DNA Synthesis And Production Company Secures $35 Million - Pulse 2.0
Elegen: DNA Synthesis And Production Company Secures $35 Million - Pulse 2.0
May 14 · Business Wire
Elegen Raises $35 Million in Series B to Accelerate Expansion into Clinical Manufacturing - Business Wire
Elegen Raises $35 Million in Series B to Accelerate Expansion into Clinical Manufacturing - Business
Jan 1 · synbiobeta.com
Cain McClary - SynBioBeta
Cain McClary - SynBioBeta
Mar 29 · news.tulane.edu
Medical Students to Train at NIH - News - Tulane University

Related Questions

What are some of the notable startups that KdT Ventures has invested in?
How did Cain McClary's discovery of the genetic mutation in ameloblastoma impact his career?
What is the focus of KdT Ventures' investment strategy?
How does Cain McClary's background in both medicine and venture capital influence his investment decisions?
What are some of the key projects Cain McClary has worked on at Grand Rounds?
Cain McClary, MD
Cain McClary, MD, photo 1
Cain McClary, MD, photo 2
Add to my network

Location

Austin, Texas, United States